Sotera Health Co (SHC) Q4 2025 Earnings Call Transcript

Why It Matters

The upgraded outlook and improved profitability signal stronger cash flow and lower leverage, enhancing shareholder value and positioning Sotera for continued expansion in the medical‑device sterilization market.

Key Takeaways

• Revenue $294M, +6.4% YoY.
• Adjusted EBITDA $151M, margin 51.2%.
• Sterogenics drives 10.5% revenue growth.
• Nelson Labs margin expands 514 bps.
• Guidance raised: 2025 revenue 4.5‑6% growth.

Pulse Analysis

Sotera Health’s second‑quarter results underscore a resilient business model anchored by its Sterigenics and Nelson Labs divisions. Sterigenics delivered a 10.5% revenue jump, fueled by higher volumes from core medical‑device customers and a nascent bioprocessing platform that benefitted from recent capacity expansions. Meanwhile, Nelson Labs leveraged pricing discipline and mix optimization to achieve a striking 514‑basis‑point margin improvement, offsetting a modest revenue dip in its Expert Advisory Services line. Together, these segment dynamics propelled consolidated revenue to $294 million and lifted adjusted EBITDA to $151 million, reflecting robust operating leverage.

The company’s balance sheet also strengthened, with operating cash flow of $57 million and total available liquidity of $918 million, while net leverage fell to 3.5×. Capital expenditures were trimmed to $170‑$180 million for 2025, a quarter of which stems from cost‑saving initiatives, freeing cash for strategic projects. A notable tax advantage emerged from recent U.S. legislation allowing up to 30% of EBITDA to be deducted as interest expense, compressing the effective tax rate to the low‑30% range. These financial levers support Sotera’s target of generating $500‑$600 million of free cash flow between 2025 and 2027.

Looking ahead, Sotera raised its full‑year guidance, forecasting 4.5‑6% constant‑currency revenue growth and 6‑7.5% adjusted EBITDA growth, while adjusting EPS expectations upward to $0.75‑$0.82. The outlook reflects confidence that foreign‑currency headwinds will be neutral and that the company can sustain margin expansion despite a projected mid‑teens Q4 revenue dip in Nordion due to cobalt‑60 shipment timing. Investors should view the upgraded outlook as a catalyst for the stock, given the combination of stronger cash generation, disciplined capital allocation, and a clear path toward lower leverage and higher free cash flow.